Management – Paul G Higham

Immatics, a leading cancer immunotherapy company, is beginning the next phase of its growth developing a number of important new technologies, having recently announced the major agreement with the University of Texas MD Anderson Cancer Center and the launch of Immatics US, Inc., a new company aiming to become a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumour types.

At the start of this next stage, the management team is to be realigned to best fit the Company's needs for the future. In agreement with the Board, Paul Higham will step aside from his role as CEO as of today.

In order to continue to support the Company and Board during the transition phase to a new CEO, Paul has agreed to act in an advisory role from the end of August and until his successor has been appointed.

Peter Chambré, Chairman of the Board said:

"on behalf of the Board and the whole organization, I would like to thank Paul for his excellent leadership of Immatics over the past 7 years. Over this period, the Company has grown and developed successfully into a leading cancer immunotherapy company with exceptional technologies, capabilities and growth opportunities. Immatics is now very well positioned to develop new cancer immunotherapies that will have an important impact on the lives of cancer patients".

Press Contact

Dr Nikola Wiegeler

Press contact,
Immatics Biotechnologies GmbH

+49 7071 5397-0

Go back